HRP20030870B1 - Aripiprazole oral solution - Google Patents
Aripiprazole oral solutionInfo
- Publication number
- HRP20030870B1 HRP20030870B1 HR20030870A HRP20030870A HRP20030870B1 HR P20030870 B1 HRP20030870 B1 HR P20030870B1 HR 20030870 A HR20030870 A HR 20030870A HR P20030870 A HRP20030870 A HR P20030870A HR P20030870 B1 HRP20030870 B1 HR P20030870B1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- oral solution
- aripiprazole
- solution
- aripiprazole oral
- Prior art date
Links
- 229940072100 aripiprazole oral solution Drugs 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 239000004097 EU approved flavor enhancer Substances 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960004372 aripiprazole Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 235000019264 food flavour enhancer Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 239000003186 pharmaceutical solution Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28671801P | 2001-04-25 | 2001-04-25 | |
| PCT/US2002/013048 WO2002085366A1 (en) | 2001-04-25 | 2002-04-24 | Aripiprazole oral solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20030870A2 HRP20030870A2 (en) | 2004-06-30 |
| HRP20030870B1 true HRP20030870B1 (en) | 2011-10-31 |
Family
ID=23099862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030870A HRP20030870B1 (en) | 2001-04-25 | 2003-10-24 | Aripiprazole oral solution |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6977257B2 (xx) |
| EP (2) | EP2436384B2 (xx) |
| JP (1) | JP4401077B2 (xx) |
| KR (1) | KR100909329B1 (xx) |
| CN (1) | CN1512884B (xx) |
| AR (1) | AR033168A1 (xx) |
| AT (1) | ATE537831T1 (xx) |
| AU (1) | AU2002254722B2 (xx) |
| BG (1) | BG66177B1 (xx) |
| BR (1) | BR0208986A (xx) |
| CA (1) | CA2445276C (xx) |
| CY (1) | CY1112606T1 (xx) |
| CZ (1) | CZ306181B6 (xx) |
| DK (1) | DK1381367T3 (xx) |
| EE (1) | EE05581B1 (xx) |
| ES (1) | ES2377855T3 (xx) |
| GE (1) | GEP20053602B (xx) |
| HK (2) | HK1058316A1 (xx) |
| HR (1) | HRP20030870B1 (xx) |
| HU (1) | HU230456B1 (xx) |
| IL (2) | IL158202A0 (xx) |
| IS (1) | IS2863B (xx) |
| MX (1) | MXPA03009728A (xx) |
| MY (1) | MY129350A (xx) |
| NO (1) | NO324606B1 (xx) |
| NZ (1) | NZ528550A (xx) |
| PE (1) | PE20021086A1 (xx) |
| PL (1) | PL206882B1 (xx) |
| PT (1) | PT1381367E (xx) |
| RS (1) | RS52082B (xx) |
| RU (1) | RU2295960C2 (xx) |
| SK (1) | SK287948B6 (xx) |
| TW (1) | TWI337865B (xx) |
| UA (1) | UA76144C2 (xx) |
| UY (1) | UY27273A1 (xx) |
| WO (1) | WO2002085366A1 (xx) |
| ZA (1) | ZA200307797B (xx) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770478B2 (en) * | 2000-02-10 | 2004-08-03 | The Regents Of The University Of California | Erythrocytic cells and method for preserving cells |
| DE60327225D1 (de) * | 2002-08-20 | 2009-05-28 | Bristol Myers Squibb Co | Aripiprazol-komplex-formulierung und verfahren |
| CN1867359B (zh) * | 2003-10-08 | 2010-12-15 | 马林克罗特公司 | 哌甲酯溶液及其制药用途和制备方法 |
| JP4836797B2 (ja) * | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
| CA2552988A1 (en) * | 2004-01-21 | 2005-08-04 | Janssen Pharmaceutica Nv | Mitratapide oral solution |
| JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
| US8865722B2 (en) * | 2006-01-05 | 2014-10-21 | Teva Pharmaceutical Industries Ltd. | Wet formulations of aripiprazole |
| CN101351193A (zh) * | 2006-01-05 | 2009-01-21 | 特瓦制药工业有限公司 | 阿立哌唑的干法制剂 |
| JP4892264B2 (ja) * | 2006-03-30 | 2012-03-07 | 高田製薬株式会社 | リスペリドン水性液剤 |
| ATE523602T1 (de) | 2006-06-12 | 2011-09-15 | Hadasit Med Res Service | Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| DK2170279T3 (en) * | 2007-07-31 | 2018-03-12 | Otsuka Pharma Co Ltd | PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION |
| WO2009042166A1 (en) * | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| WO2010146872A1 (ja) * | 2009-06-19 | 2010-12-23 | 株式会社メドレックス | アリピプラゾールと有機酸を有効成分とする外用剤組成物 |
| TR201000948A1 (tr) | 2010-02-09 | 2011-08-22 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Aripiprazol formülasyonları. |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| EP2609923B1 (en) | 2010-03-31 | 2017-05-24 | Gilead Pharmasset LLC | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
| AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
| HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
| JO3410B1 (ar) * | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | تركيبة أريبيبرازول مجفف بالتبريد |
| CN102846616B (zh) * | 2011-06-27 | 2015-05-06 | 上海中西制药有限公司 | 一种阿立哌唑制剂及其制备方法 |
| US9241876B2 (en) | 2011-06-27 | 2016-01-26 | Shanghai Zhongxi Pharmaceutical Corporation | Aripiprazole medicament formulation and preparation method therefor |
| TWI632921B (zh) * | 2011-10-19 | 2018-08-21 | 大塚製藥股份有限公司 | 口服溶液 |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| CA2867123C (en) | 2012-03-19 | 2021-02-16 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US20150174247A1 (en) * | 2012-06-29 | 2015-06-25 | Maruishi Pharmaceutical Co., Ltd. | Oral pharmaceutical preparation of aripiprazole |
| JP5341282B1 (ja) * | 2012-06-29 | 2013-11-13 | 丸石製薬株式会社 | アリピプラゾールの経口医薬製剤 |
| KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
| US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| US9452134B2 (en) * | 2012-09-26 | 2016-09-27 | Bristol-Myers Squibb Company | Apixaban solution formulations |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US20140107130A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals, LLC | Oral Solution Formulations of Aripiprazole |
| PL2908859T3 (pl) * | 2012-10-16 | 2017-10-31 | Arven Ilac Sanayi Ve Ticaret As | Formulacje arypiprazolu |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6203682B2 (ja) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | アリピプラゾール含有水性液剤 |
| CN103393594A (zh) * | 2013-08-22 | 2013-11-20 | 万特制药(海南)有限公司 | 一种新的阿立哌唑的制剂组合物 |
| CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| WO2016189504A1 (en) * | 2015-05-28 | 2016-12-01 | Leiutis Pharmaceuticals Pvt Ltd | Non-lyophilized compositions of aripiprazole and methods of preparation thereof |
| JP6039849B1 (ja) * | 2015-06-12 | 2016-12-07 | 高田製薬株式会社 | アリピプラゾール含有内用液剤 |
| WO2017025930A1 (en) * | 2015-08-12 | 2017-02-16 | Ftf Pharma Private Limited | Oral solution of aripiprazole |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
| CN108434146A (zh) * | 2017-02-16 | 2018-08-24 | 天津国际生物医药联合研究院 | 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用 |
| CN109498556A (zh) * | 2017-09-15 | 2019-03-22 | 万特制药(海南)有限公司 | 阿立哌唑口服溶液及其制备方法 |
| CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
| CN112666267B (zh) * | 2019-10-15 | 2023-09-26 | 上海上药中西制药有限公司 | 一种阿立哌唑药品有关物质的检测方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU843739A3 (ru) | 1978-02-17 | 1981-06-30 | Карл Томэ Гмбх (Фирма) | Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| PH17194A (en) * | 1980-03-06 | 1984-06-19 | Otsuka Pharma Co Ltd | Novel carbostyril derivatives,and pharmaceutical composition containing the same |
| JPS5959663A (ja) | 1982-09-29 | 1984-04-05 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体−シクロデキストリン包接化合物 |
| JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5457099A (en) | 1992-07-02 | 1995-10-10 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
| TW254855B (xx) * | 1993-07-28 | 1995-08-21 | Otsuka Pharma Co Ltd | |
| WO1998043673A1 (en) * | 1997-03-31 | 1998-10-08 | Johnson & Johnson Consumer Companies, Inc. | Solvent system for enhanced penetration of pharmaceutical compounds |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| JP2002524397A (ja) * | 1998-09-03 | 2002-08-06 | アルサイド コーポレーション | 耐凍結性の局所用殺菌剤及びそれに関連する方法 |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) * | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
-
2002
- 2002-03-28 MY MYPI20021124A patent/MY129350A/en unknown
- 2002-04-15 AR ARP020101366A patent/AR033168A1/es unknown
- 2002-04-19 TW TW091108139A patent/TWI337865B/zh not_active IP Right Cessation
- 2002-04-24 PT PT02723964T patent/PT1381367E/pt unknown
- 2002-04-24 CZ CZ2003-2821A patent/CZ306181B6/cs not_active IP Right Cessation
- 2002-04-24 RU RU2003132426/15A patent/RU2295960C2/ru not_active IP Right Cessation
- 2002-04-24 EE EEP200300523A patent/EE05581B1/xx not_active IP Right Cessation
- 2002-04-24 DK DK02723964.9T patent/DK1381367T3/da active
- 2002-04-24 WO PCT/US2002/013048 patent/WO2002085366A1/en active IP Right Grant
- 2002-04-24 EP EP11190103.9A patent/EP2436384B2/en not_active Expired - Lifetime
- 2002-04-24 UA UA20031110599A patent/UA76144C2/uk unknown
- 2002-04-24 UY UY27273A patent/UY27273A1/es not_active Application Discontinuation
- 2002-04-24 CN CN028112148A patent/CN1512884B/zh not_active Ceased
- 2002-04-24 NZ NZ528550A patent/NZ528550A/en not_active IP Right Cessation
- 2002-04-24 IL IL15820202A patent/IL158202A0/xx active IP Right Grant
- 2002-04-24 ES ES02723964T patent/ES2377855T3/es not_active Expired - Lifetime
- 2002-04-24 HU HU0303946A patent/HU230456B1/hu not_active IP Right Cessation
- 2002-04-24 EP EP02723964A patent/EP1381367B1/en not_active Expired - Lifetime
- 2002-04-24 MX MXPA03009728A patent/MXPA03009728A/es active IP Right Grant
- 2002-04-24 AU AU2002254722A patent/AU2002254722B2/en not_active Expired
- 2002-04-24 PL PL364666A patent/PL206882B1/pl unknown
- 2002-04-24 JP JP2002582939A patent/JP4401077B2/ja not_active Expired - Lifetime
- 2002-04-24 SK SK1264-2003A patent/SK287948B6/sk not_active IP Right Cessation
- 2002-04-24 AT AT02723964T patent/ATE537831T1/de active
- 2002-04-24 US US10/131,304 patent/US6977257B2/en not_active Expired - Lifetime
- 2002-04-24 CA CA002445276A patent/CA2445276C/en not_active Expired - Fee Related
- 2002-04-24 KR KR1020037013943A patent/KR100909329B1/ko active IP Right Grant
- 2002-04-24 BR BR0208986-6A patent/BR0208986A/pt active Search and Examination
- 2002-04-24 RS YU84703A patent/RS52082B/sr unknown
- 2002-04-24 GE GE5332A patent/GEP20053602B/en unknown
- 2002-04-25 PE PE2002000346A patent/PE20021086A1/es not_active Application Discontinuation
-
2003
- 2003-10-01 IL IL158202A patent/IL158202A/en not_active IP Right Cessation
- 2003-10-01 BG BG108216A patent/BG66177B1/bg unknown
- 2003-10-06 ZA ZA200307797A patent/ZA200307797B/en unknown
- 2003-10-14 IS IS6994A patent/IS2863B/is unknown
- 2003-10-21 NO NO20034705A patent/NO324606B1/no not_active IP Right Cessation
- 2003-10-24 HR HR20030870A patent/HRP20030870B1/xx not_active IP Right Cessation
-
2004
- 2004-02-19 HK HK04101190.2A patent/HK1058316A1/xx not_active IP Right Cessation
-
2012
- 2012-03-14 CY CY20121100273T patent/CY1112606T1/el unknown
- 2012-09-28 HK HK12109608.1A patent/HK1168792A1/xx not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20030870B1 (en) | Aripiprazole oral solution | |
| RS50360B (sr) | Farmaceutske formulacije derivata platine | |
| HRP20010332B1 (en) | Pharmaceutical moxifloxacin preparation | |
| MX9600857A (es) | Forma de dosificacion i en tabletas, con unidades multiples. | |
| WO2005045689A3 (en) | Methods and systems for network coordination | |
| EE04275B1 (et) | Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid | |
| DE69627147D1 (de) | Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung | |
| DE60132600D1 (de) | Medikamente zur chemotherapeutischen behandlung von erkrankungen | |
| RS51737B (sr) | Korišćenje inhibitora il-18 | |
| ATE304013T1 (de) | 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| ME00578A (en) | Use of gastrointestinal lipase inhibitors | |
| HRP20030050B1 (en) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | |
| IS6956A (is) | Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því | |
| DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
| RS49599B (sr) | Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija | |
| NO20026212L (no) | Forbindelse for medikamentavleveringssystem og fremgangsmåte for fremstilling av forbindelsen | |
| DE60138629D1 (de) | Laspartomycin-derivate, sowie ihre herstellung und verwendung | |
| DE69711633D1 (de) | Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung | |
| TR199903065T2 (xx) | Oral uygulamaya y�nelik rapamisin form�lasyonlar�. | |
| NO994679L (no) | Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist | |
| HRP20000703B1 (en) | Stabile compositions levosimendan and alginic acid | |
| RS51316B (sr) | Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli | |
| DE69927997D1 (de) | Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung | |
| DE60029979D1 (de) | LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT | |
| NO20041878D0 (no) | Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: BRISTOL-MYERS SQUIBB COMPANY, US |
|
| PPPP | Transfer of rights |
Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JP |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20180410 Year of fee payment: 17 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20190424 |